52 results about "Cutaneous Disorders" patented technology

The present invention relates to a novel microneedle platform for minimally invasive delivery of therapeutic agents and the modulation of the neuro-immune axis in deep tissue. The present invention also adopts an innovative approach for minimally invasive and precisely controllable treatment of deep cutaneous diseases, conditions, and disorders using said electroconductive MN patch, which has the potential to benefit millions of patients worldwide.

A new method of treating a skin disease or condition in a human subject caused by a parasite, particularly Demodex mite infestations that result in demodicosis, with moxidectin. The demodicosis is typically Demodex blepharitis.

The present invention discloses a polypeptide combination wound healing preparation with high permeability, specifically relating to a polypeptide combination of tripeptide-1, hexapeptide-9, and palmitoyl-modified peptide, and a new use for treating skin diseases such as wounds, ulcers, burns, scars, and keloids. While the polypeptide combination plays a significant synergistic effect in wound healing, it can effectively prevent and inhibit scar hyperplasia. In addition, the polypeptide combination wound healing preparation of the present invention utilizes the wound healing promoting activity of the composite polypeptide, and is compounded with specific penetration enhancers and antioxidants to be prepared into a gel with functions of moisturizing, promoting healing, reducing infection, and relieving pain, greatly increasing skin penetration, significantly enhancing the skin retention dose, and having significant antibacterial, anti-inflammatory, eschar-removing and muscle-generating, astringent healing, and scar hyperplasia inhibiting effects, being particularly suitable for wound healing and reducing scar residue.

Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.

The invention provides application of licorcidine and an inclusion compound thereof in preparation of a malassezia furfur antibacterial agent, belongs to the technical field of biological medicines, and discloses a remarkable inhibition effect of licorcidine on malassezia furfur for the first time, and the licorcidine is prepared into the inclusion compound to increase water solubility so as to be further used for inhibiting malassezia furfur. The preparation method of the licorcidine inclusion compound comprises the following steps: dropwise adding a licorcidine solution into a beta-hydroxypropyl cyclodextrin solution, and mixing to obtain a mixed solution; and removing the solvent of the mixed solution, resuspending with water, and removing insoluble substances to obtain the product. The MIC of the glycyrrhizine to the malassezia furfur strain is 25 [mu] g / mL, and the MIC of the glycyrrhizine inclusion compound to the malassezia furfur strain is 12.5 [mu] g / mL; compared with a chemically synthesized antibacterial component, the licorcidine or licorcidine inclusion compound has better biocompatibility and safety, can be used for treating skin diseases caused by malassezia furfur, and has wide application potential.

This invention discloses a traditional Chinese medicine composition for treating HPV infection, its preparation, and its uses. The composition comprises the following ingredients in the indicated weight percentages: 10-40 parts of *Hedyotis diffusa*, 10-30 parts of *Smilax glabra*, 10-30 parts of *Hedyotis diffusa*, 10-30 parts of *Paeonia suffruticosa*, 10-40 parts of *Lithospermum erythrorhizon*, 10-30 parts of *Dictamnus dasycarpus*, 10-30 parts of *Radix Paeoniae Rubra*, 10-30 parts of *Cicadae Periostracum*, 10-30 parts of *Astragalus membranaceus*, and 10-30 parts of *Glycyrrhiza uralensis*. It effectively inhibits the replication of human papillomavirus (HPV) nucleic acid, thereby effectively treating cervical HPV infection caused by HPV, as well as infectious skin diseases such as cervical precancerous lesions and condyloma acuminata caused by HPV infection.

The present invention relates to a pharmaceutical composition, quasi-drug composition, or cosmetic composition for the prevention, improvement, or treatment of skin diseases, comprising as an active ingredient a tubulin inhibitor and one or more compounds selected from the group consisting of calcium, colchicine, tapinarof, fingolimod, tofacitinib, and pharmaceutically acceptable salts thereof. The combination therapy of the present invention can be used as an active ingredient that simultaneously exhibits activities such as skin moisturizing, whitening, wrinkle improvement, acne relief, skin barrier strengthening, or keratinocyte differentiation, along with the prevention, treatment, or improvement of skin diseases.

The present invention relates to novel compounds and pharmaceutical compositions thereof, and to methods for promoting healthy skin aging, treating skin disorders, treating cardiovascular disorders, treating renal disorders, treating angiogenesis disorders, such as cancer, treating tissue damage, such as non-cardiac tissue damage, treating progressive myocardial infarction, and treating various other disorders, such as complications resulting from diabetes with the compounds and compositions of the invention. Other disorders may include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, skin infections, peripheral vascular disease, stroke, and the like.

There is provided a compound of formula I, X-Y (I) wherein: Y comprises a peptide fragment of formula IV, [Ala] m-[Lys-V] n-Lys-V (IV) wherein m represents 0 or 1, n represents the integer 0, 1, 2, 3 or 4, and each V independently represents a sequence of 2 to 4 amino acids wherein the amino acids are selected from one or more of the group consisting of Lys, Pro, Hyp, diHyp, Thr, pThr, DOPA, Tyr and Ser; and X represents at least one optional substituent selected from the group consisting of: (i) a lipid selected from the group consisting of vitamin A, vitamin E, cholesterol and fatty acids comprising one or more carboxylic acid groups, 1 to 50 carbons and / or one or more cyclic rings, said lipids being linear or branched, saturated or unsaturated with between 1 and 10 carbon-carbon double bonds and / or substituted with between 1 and 10-OH groups, or a derivative of any of these lipids; and / or (ii) a non-steroidal anti-inflammatory agent, which compounds may be used in medicine, including as pharmaceutical excipients, adhesives and film-forming materials, and / or may be used in the treatment of conditions characterized by inflammation, including wounds, burns and mucosal disorders such as skin diseases, oral diseases, gynecological diseases and IBD.

The invention discloses a handheld nitric oxide treatment device for preventing and treating skin diseases. The rotating gliding arc discharge technology is adopted, and a high-density local energy field is formed in air, so that nitrogen and oxygen molecules efficiently react to generate NO and NO2. NO gas flow with stable concentration can be generated under the condition of low-voltage power supply, and in-situ treatment of the skin surface is realized. The USB PD standard power supply is applied to the NO treatment device for the first time, so that the energy required by discharge driving is ensured, and the safety risk of high-voltage direct supply is avoided. In addition, a discharge module, an airflow channel and a heat dissipation structure in the device adopt an integrated layout, and triple cooperation of airflow driving, discharge generation and cooling is realized. The adjustability of the proportion of the active components is realized by controlling the discharge power and the airflow speed, and the treatment effect and the biological safety can be both considered. The invention can be widely applied to the scenes of home nursing, adjuvant therapy of skin diseases, wound disinfection, post-medical and post-art recovery and the like.

A system for treatment of wounds consists of a treatment housing, a fluid delivery mechanism for supplying debridement fluids to the wound treatment area, an evacuation mechanism for evacuation of debris from the treatment chamber. A handheld device is connected to the treatment housing, wherein its interior accommodates a laser source, a scanning device, an image recording device and at least one sensor / detector, a control unit having a microprocessor for controlling operation of the system. The sensors detect concentration of various substances in the wound, and microprocessors analyze data obtained by the sensors and generate signals to adjust parameters of the laser, the liquid dispensing nozzles and the suction outlet to optimize removal of necrotic tissue, to promote wound healing.

According to the preparation method of the chlorogenic acid-methotrexate soluble microneedle, chondroitin sulfate and a methyl vinyl ether-maleic anhydride copolymer are adopted as matrix materials, and the drug-loaded microneedle is prepared through a two-step centrifugation method. The length of a needle body of the prepared microneedle is about 500 microns, the microneedle has good mechanical strength and skin puncture performance, the microneedle can be basically dissolved within 2 hours, the average drug content of chlorogenic acid is 57.97 + / -1.76 mu g / tablet, and the average drug content of methotrexate is 56.32 + / -1.67 mu g / tablet. An in-vitro percutaneous penetration test shows that the 6-hour cumulative transdermal rate of chlorogenic acid reaches 93.96%, the 6-hour cumulative transdermal rate of methotrexate reaches 86.92%, which are respectively 22.1 times and 3.0 times that of a control solution group, so that the efficient percutaneous delivery of the medicine is realized. The microneedle is small in skin irritation, the skin barrier can be naturally repaired within 15 minutes after puncture, and a new administration approach is provided for treatment of skin diseases such as psoriasis.

Disclosed are methods for treating an autoimmune and / or an inflammatory disease, disorder, or condition, including a skin disease, disorder, or condition comprising orally administering a prodrug of itaconate, 4-methyl itaconate, or 1-methyl itaconate to a subject in need of treatment thereof.

The present invention relates to a pharmaceutical composition for preventing or treating skin diseases caused by radiation irradiation, comprising darapladib or a pharmaceutically acceptable salt thereof as an active ingredient. Darapladib improves damaged skin due to radiation irradiation, such as maintaining the water loss amount, water content level and pH level of damaged skin due to radiation irradiation, and recovering skin thickness and adipocyte area, and thus can be effectively used as a composition for preventing, treating or ameliorating skin diseases caused by radiation irradiation.

The invention discloses herbal essence essential oil extracted from ancient prescription traditional Chinese medicines. The composition is composed of a basic formula, carrier oil, a synergist and a flavoring agent. A basic formula contains multiple traditional Chinese medicines such as clove and radix aucklandiae, for example, clove can resist bacteria and inflammation, and pearl powder can whiten and moisten skin. Camellia oil is selected as carrier oil and has moistening and absorption promoting effects. The synergist contains sulfur, a potassium permanganate solution and the like and has synergistic sterilization and anti-inflammation effects. The flavoring agent is edible-grade essence, so that the smell is improved, and the mood is relieved. The preparation method comprises the following steps: pretreating the basic formula components, soaking the carrier oil, preparing the synergist, blending twice, mixing with the synergist and the like. The essential oil is comprehensive in efficacy, can be externally applied to treat skin diseases, can be used for relieving arthropathy through essential oil massage and improving various body discomforts through abdomen massage, is natural and safe, is scientific in formula, and has great application value in the fields of medical treatment, health care and skincare.

Described herein is a method of reducing a sign or symptom of a dermal disorder in a subject in need of treatment for the dermal disorder by topically applying a topical silk fibroin composition once or more daily to the site of the dermal disorder, wherein the silk fibroin formulation includes no additional dermal therapeutic agents. Also included are methods of reducing topical steroid use in a subject in need of treatment for a dermal disorder.

Described herein is a method of reducing a sign or symptom of a dermal disorder in a subject in need of treatment for the dermal disorder by topically applying a topical silk fibroin composition once or more daily to the site of the dermal disorder, wherein the silk fibroin formulation includes no additional dermal therapeutic agents. Also included are methods of reducing topical steroid use in in a subject in need of treatment for a dermal disorder.

The invention belongs to the technical field of medicines, and particularly relates to a benvimod solution composition, a pharmaceutical preparation containing the benvimod solution composition, and a preparation method and application of the benvimod solution composition. The composition comprises benvimod or a pharmaceutically acceptable salt thereof, a solubilizer, a solvent and water, and optionally comprises a penetration enhancer, an antioxidant, a bacteriostatic agent, a chelating agent, a pH regulator and a thickening agent. The composition disclosed by the invention can effectively relieve symptoms of inflammatory skin diseases and has an obvious improvement effect on skin injury, so that the composition has excellent drug effect and safety and can also obviously improve the compliance of patients.

The present invention relates to a male / female groin care dryer. The male / female groin care dryer is provided on the walls or lockers of shower facilities in gyms, public baths, golf courses, swimming pools and the like so as to be conveniently usable by both men and women in a way that the male / female groin care dryer is used to dry the Y-zone (groin) after drying off with towels post-shower, thereby being a hygiene product capable of preventing skin diseases related to the groin. The male / female groin care dryer has a simple structure, can be manufactured at low costs and at low unit price through mass production so as to reduce the burden of purchasing costs, and thus can be widely distributed and used.

The present invention relates to a cooling garment, and more particularly, to a cooling garment that, when simply worn on the body of a worker in a special environment such as a construction site, industrial facilities, agriculture, etc., prevents heat stroke, dehydration, fatigue, and other health problems caused by an increase in body temperature in summer, prevents discomfort and skin diseases caused by the wetting of a work garment by sweat, and not only that, maintains a comfortable environment even in hot weather in daily life, sports, or outdoor activities, and further, prevents a decrease in concentration and fatigue accumulation caused by a long-term increase in body temperature, thereby ensuring the safety and physical activity efficiency of a user.

The present invention includes compositions and methods for treating or preventing certain dermal disorders including dermal atrophy, pseudoscars, actinic keratosis, seborrheic or actinic keratoses, lentigines, focal areas of dermal thickening, and coarse wrinkles. In certain embodiments, the compositions useful within the invention comprise a therapeutically effective amount of a mTORC1 inhibitor and a dermatologically acceptable carrier.

The invention discloses a double-layer microneedle delivery system for acne treatment as well as a preparation method and application of the double-layer microneedle delivery system, and belongs to the technical field of biomedical materials and infectious skin disease treatment. According to the double-layer microneedle delivery system, a copper-tannic acid compound is packaged in a needle tip layer, and probiotic outer membrane vesicles are loaded on a backing layer, so that an intelligent delivery platform with a time-space graded release characteristic is constructed. According to the double-layer structural design, the technical problem of multi-component sequential release is solved, the organic integration of antibacterial, anti-inflammatory and repairing functions is realized, and a new treatment strategy which is efficient, low in side effect and capable of preventing scar formation is provided for acne and other complex skin inflammatory diseases.

Pharmaceutical compositions of alpha-lipoic acid and / or methylsulfonylmethane (MSM) and magnesium salts, useful for the treatment, prevention, or reduction of the severity of viral infections and / or skin diseases, are provided herein. Methods for preparing the pharmaceutical compositions and methods for using the pharmaceutical compositions in therapeutic treatments are also provided.

The invention discloses indole-3-lactic acid loaded beta-glucan modified PLGA nanoparticles, and relates to the technical field of nano-drug delivery and skin disease treatment, and the indole-3-lactic acid loaded beta-glucan modified PLGA nanoparticles comprise the following steps: 1, preparing a solution; preparing a solution 1 and a solution 2; 2, emulsifying and forming nano-particles; dropwise adding the solution 2 into the continuously stirred solution 1; adding deionized water while continuously stirring, and carrying out ultrasonic treatment for 10-20 minutes to promote the volatilization of dichloromethane DCM; performing centrifugal washing, removing polyvinylpyrrolidone (PVP) and residual solvent, and performing vacuum drying to obtain polylactic acid-glycolic acid copolymer (PLGA) nanoparticles; step 3, beta-glucan modification: preparing a beta-glucan solution with a concentration of 2 mg / mL according to a mass ratio of 1: 1, and adding a PLGA (at) drug NPs suspension; performing ultrasonic dispersion for 30 minutes and stirring overnight; and carrying out centrifugal washing to remove uncombined beta-glucan, so as to obtain a final product, namely the PLGA (at) drg-beta-glucan nano-particles.

Provided are methods of regulating proliferation and / or differentiation of keratinocytes and immune cells, more specifically to methods of treating pathologies characterized by hyperproliferative keratinocytes or inflammatory skin diseases by administration of FABP4-inhibitor.

Novel retinamides with unique properties and biological activities, including inhibition of retinoic acid metabolism and modulation of Mnk1 / 2-eIF4E and androgen receptor (AR) signaling pathways, are synthesized and developed. The novel retinamides are capable of effecting treatment of a variety of dermatological conditions while limiting adverse side effects.